Transcode Therapeutics Inc (RNAZ)

$8.52 -0.15 (-1.73%)
Market Cap 7.81M
Revenue (ttm) 0.00
Net Income (ttm) -34.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,200
Avg Vol 11,192
Day's Range N/A - N/A
Shares Out 917,000.00
Stochastic %K 9%
Beta 1.49
Analysts Strong Buy
Price Target $10.00

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 837 3099
Address:
6 Liberty Square, Suite 2382, Boston, United States
DisneyPalaceTrades
DisneyPalaceTrades Apr. 23 at 5:59 PM
$RNAZ
0 · Reply
Vedran1
Vedran1 Apr. 22 at 3:22 AM
$RNAZ 13G 4-20-26 https://www.sec.gov/Archives/edgar/data/0001829635/000110465926045551/xslSCHEDULE_13G_X02/primary_doc.xml
1 · Reply
Zeusgodmd
Zeusgodmd Apr. 19 at 11:43 PM
$RNAZ Lilly buying a company out for 2 billion. Let’s see our day.
0 · Reply
TheUnmaker
TheUnmaker Apr. 18 at 1:57 PM
$RNAZ too quiet
1 · Reply
Vedran1
Vedran1 Apr. 16 at 4:05 PM
$RNAZ I'll try to add a few shares today around 8.7.
1 · Reply
BiotechGoldenEra
BiotechGoldenEra Apr. 16 at 2:46 AM
$RNAZ rnizzled
1 · Reply
Vedran1
Vedran1 Apr. 15 at 10:57 PM
$RNAZ 10k (did not read it yet) https://www.sec.gov/ix?doc=/Archives/edgar/data/0001829635/000110465926043810/rnaz-20251231x10k.htm
1 · Reply
MetricWhale
MetricWhale Apr. 14 at 1:51 PM
$RNAZ watching it here could go with volume
0 · Reply
Hovius
Hovius Apr. 13 at 2:01 PM
$RNAZ are they diluting without any positive news? these guys.. 🤣🤣🤣
1 · Reply
Vedran1
Vedran1 Apr. 13 at 12:48 PM
$RNAZ Just a general read here, from BBC: --- A new wave of immunotherapy is eliminating cancers After nearly 100 years of development, treatments that bolster the body's immune system to fight cancer are coming of age – and saving patients' lives. https://www.bbc.com/future/article/20260410-how-a-new-wave-of-immunotherapy-is-eliminating-cancers
0 · Reply
Latest News on RNAZ
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

Apr 7, 2026, 8:30 AM EDT - 18 days ago

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Mar 3, 2026, 8:01 AM EST - 7 weeks ago

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

Feb 23, 2026, 8:01 AM EST - 2 months ago

TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

Feb 5, 2026, 8:04 AM EST - 2 months ago

TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

Jan 6, 2026, 8:01 AM EST - 3 months ago

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

Dec 22, 2025, 8:01 AM EST - 4 months ago

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

Dec 11, 2025, 8:05 AM EST - 4 months ago

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

Nov 17, 2025, 8:01 AM EST - 5 months ago

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

Oct 14, 2025, 8:06 AM EDT - 6 months ago

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 28, 2025, 8:00 AM EDT - 11 months ago

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 8, 2025, 8:05 AM EDT - 1 year ago

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 5, 2025, 5:07 PM EDT - 1 year ago

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 1 year ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

May 1, 2025, 9:01 AM EDT - 1 year ago

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Apr 21, 2025, 4:37 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Mar 27, 2025, 4:37 PM EDT - 1 year ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Mar 25, 2025, 6:24 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 23, 2025, 11:11 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Mar 13, 2025, 7:47 AM EDT - 1 year ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Results of Special Meeting

Feb 25, 2025, 4:15 PM EST - 1 year ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

Feb 6, 2025, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Jan 14, 2025, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Jan 7, 2025, 8:00 AM EST - 1 year ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Dec 18, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Nov 29, 2024, 4:25 PM EST - 1 year ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Nov 27, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Nov 5, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Sep 17, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Sep 5, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Jul 24, 2024, 4:05 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Jul 22, 2024, 10:30 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jul 22, 2024, 4:07 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

May 29, 2024, 9:15 AM EDT - 2 years ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:30 AM EDT - 2 years ago

TransCode Therapeutics Open Letter to Shareholders

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Apr 15, 2024, 9:00 AM EDT - 2 years ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Apr 3, 2024, 9:10 AM EDT - 2 years ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Mar 28, 2024, 8:30 AM EDT - 2 years ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Mar 11, 2024, 9:00 AM EDT - 2 years ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Mar 6, 2024, 4:15 PM EST - 2 years ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Feb 20, 2024, 8:00 AM EST - 2 years ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Jan 31, 2024, 4:05 PM EST - 2 years ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Jan 29, 2024, 8:30 AM EST - 2 years ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Jan 22, 2024, 4:45 PM EST - 2 years ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Jan 18, 2024, 1:27 PM EST - 2 years ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

Jan 12, 2024, 4:05 PM EST - 2 years ago

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 11, 2024, 8:00 AM EST - 2 years ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

Jan 4, 2024, 8:05 AM EST - 2 years ago

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Dec 12, 2023, 8:30 AM EST - 2 years ago

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

Dec 5, 2023, 9:00 AM EST - 2 years ago

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Dec 4, 2023, 4:10 PM EST - 2 years ago

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

DisneyPalaceTrades
DisneyPalaceTrades Apr. 23 at 5:59 PM
$RNAZ
0 · Reply
Vedran1
Vedran1 Apr. 22 at 3:22 AM
$RNAZ 13G 4-20-26 https://www.sec.gov/Archives/edgar/data/0001829635/000110465926045551/xslSCHEDULE_13G_X02/primary_doc.xml
1 · Reply
Zeusgodmd
Zeusgodmd Apr. 19 at 11:43 PM
$RNAZ Lilly buying a company out for 2 billion. Let’s see our day.
0 · Reply
TheUnmaker
TheUnmaker Apr. 18 at 1:57 PM
$RNAZ too quiet
1 · Reply
Vedran1
Vedran1 Apr. 16 at 4:05 PM
$RNAZ I'll try to add a few shares today around 8.7.
1 · Reply
BiotechGoldenEra
BiotechGoldenEra Apr. 16 at 2:46 AM
$RNAZ rnizzled
1 · Reply
Vedran1
Vedran1 Apr. 15 at 10:57 PM
$RNAZ 10k (did not read it yet) https://www.sec.gov/ix?doc=/Archives/edgar/data/0001829635/000110465926043810/rnaz-20251231x10k.htm
1 · Reply
MetricWhale
MetricWhale Apr. 14 at 1:51 PM
$RNAZ watching it here could go with volume
0 · Reply
Hovius
Hovius Apr. 13 at 2:01 PM
$RNAZ are they diluting without any positive news? these guys.. 🤣🤣🤣
1 · Reply
Vedran1
Vedran1 Apr. 13 at 12:48 PM
$RNAZ Just a general read here, from BBC: --- A new wave of immunotherapy is eliminating cancers After nearly 100 years of development, treatments that bolster the body's immune system to fight cancer are coming of age – and saving patients' lives. https://www.bbc.com/future/article/20260410-how-a-new-wave-of-immunotherapy-is-eliminating-cancers
0 · Reply
focafoca99
focafoca99 Apr. 7 at 9:57 PM
$RNAZ lined up financing of up to $20 million that it says could extend runway into late 2027 or early 2028.
0 · Reply
Vedran1
Vedran1 Apr. 7 at 1:29 PM
$RNAZ The date (by April 15) milestone to look forward too in the filing: "The first Pre-Paid Advance in the amount of $1.0 million is conditioned upon the Company filing its Annual Report on Form 10-K for the year ended December 31, 2025 on or prior to April 15, 2025 (“Form 10-K”) and will be disbursed to the Company concurrently with the Company’s filing of its Form 10-K."
0 · Reply
Vedran1
Vedran1 Apr. 7 at 1:09 PM
$RNAZ Here is more detailed filing1 info (I did not read it yet): https://www.sec.gov/edgar/browse/?CIK=1829635&owner=exclude
0 · Reply
Travelling
Travelling Apr. 7 at 1:05 PM
$CETX Sold last time at 9.50, holding $AIXI watching $RNAZ $CMMB $SMX
0 · Reply
marvelousTrades
marvelousTrades Apr. 7 at 1:04 PM
$RNAZ volume is anemic..
0 · Reply
Hovius
Hovius Apr. 7 at 1:00 PM
$RNAZ So… who is this new investor?
2 · Reply
Stock_Catcher
Stock_Catcher Apr. 7 at 12:32 PM
$RNAZ TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
0 · Reply
DekmarTrades
DekmarTrades Apr. 7 at 12:32 PM
$RNAZ Enters into Agreements for up to $20 Million
0 · Reply
MetricWhale
MetricWhale Apr. 7 at 12:07 PM
$RNAZ can do a large jump if it gets volume pressure at this
1 · Reply
Vedran1
Vedran1 Apr. 6 at 2:31 PM
$RNAZ will try to get 2 dozen shares at 8.6 as a day's plan.
0 · Reply
Scoty_D
Scoty_D Apr. 2 at 3:35 PM
$RNAZ
0 · Reply
Hovius
Hovius Apr. 1 at 12:54 PM
$RNAZ Looks like no news until they get their EOY statements done…
0 · Reply